ET
Therapeutic Areas
Evofem Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Phexxi® | Hormone-free, on-demand prescription contraception | Approved |
| Solosec® (secnidazole) | Treatment of bacterial vaginosis (BV) and trichomoniasis | Approved |
| EVO200 | Prevention of recurrent Bacterial Vaginosis (BV) | Phase 1 |
Leadership Team at Evofem Biosciences
SP
Saundra Pelletier
Chief Executive Officer, President, and Interim Chair of the Board
IZ
Ivy Zhang
Chief Financial Officer and Secretary
KG
Kathy Gallo-Doyle
SVP, Commercial Operations
AR
Amy Raskopf
Chief Business Development Officer
KK
Kim Kamdar, Ph.D.
Board Member
TO
Tony O'Brien
Board Member